

Central Nervous System (CNS) Therapeutics Market Report by Disease (Neurodegenerative Diseases, Neurovascular Diseases, CNS Trauma, Mental Health, Infectious Diseases, CNS Cancer, and Others), Application (Hospital, Clinic, Homecare, and Others), and Region 2024-2032

<https://marketpublishers.com/r/C6F06728C3EBEN.html>

Date: April 2024

Pages: 137

Price: US\$ 3,899.00 (Single User License)

ID: C6F06728C3EBEN

Abstracts

The global central nervous system (CNS) therapeutics market size reached US\$ 140.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US\$ 239.1 Billion by 2032, exhibiting a growth rate (CAGR) of 5.9% during 2024-2032. The growing prevalence of neurological and psychiatric disorders among the masses, the rise in telehealth and telemedicine services, and the increase in trade agreements and partnerships are among the key factors driving the market growth.

Central nervous system (CNS) therapeutics focus on the treatment and management of disorders affecting the brain and spinal cord, which make up the central nervous system. These disorders can range from neurodegenerative diseases, such as Alzheimer's and Parkinson's to psychiatric conditions such as depression and anxiety. They also cover acute conditions, including traumatic brain injuries and strokes. The treatment landscape is vast and includes various approaches, such as pharmacological interventions, surgical procedures, and newer modalities, including gene therapy. Medications can consist of antidepressants, antipsychotics, or drugs specifically designed to target neural pathways. Research in this field is continually evolving, driven by advancements in neuroscience and biotechnology.

One of the primary market drivers for the central nervous system (CNS) therapeutics industry is the rising prevalence of neurological and psychiatric disorders globally.

Conditions such as Alzheimer's, Parkinson's, depression, and anxiety are becoming increasingly common due to factors, such as an aging population, lifestyle changes, and environmental stressors. With an increasing number of patients requiring CNS therapeutics, the market potential continues to expand, making it an attractive area for investment and innovation. Along with this, the rise in telehealth and telemedicine services is proving to be a significant driver in the market growth. The COVID-19 pandemic has accelerated the adoption of remote healthcare, and this trend is likely to continue. Telehealth services make it more convenient for patients to seek medical advice and obtain prescriptions for CNS disorders without the need for physical appointments. This increased accessibility is particularly beneficial for those in remote areas, broadening the patient base for CNS therapeutics. In addition, regulatory agencies are showing an increased willingness to fast-track the approval of innovative CNS therapeutic drugs, particularly those addressing unmet medical needs. Therefore, it is contributing to the market. Moreover, trade agreements and partnerships are often facilitated by globalization, providing a more streamlined distribution network for CNS therapeutic products, and creating a positive market outlook.

Central Nervous System (CNS) Therapeutics Market Trends/Drivers:

Technological Advancements in Drug Discovery

The rapid advancements in technology have been a crucial driver for the CNS therapeutics industry. Traditional methods of drug discovery are being augmented by technologies such as artificial intelligence (AI), machine learning, and big data analytics. These technologies help in quicker identification of potential drug candidates, thereby speeding up the process of drug development. High-throughput screening methods have also become more sophisticated, allowing researchers to evaluate thousands of compounds in a shorter time frame. Bioinformatics tools and computational models are increasingly used for understanding disease pathways at the molecular level, aiding in the development of targeted therapies. These technological strides have significantly reduced the time and cost associated with bringing a new CNS therapeutic drug to market, providing a robust impetus for industry growth.

Public Awareness and Healthcare Infrastructure

Public awareness about mental health and neurological disorders has grown significantly in recent years. This increased awareness has led to early diagnosis and treatment, subsequently driving the demand for CNS therapeutics. Furthermore, governments and healthcare organizations are increasingly recognizing the importance of mental health, leading to better healthcare infrastructure and policies that facilitate

the development and distribution of CNS drugs. In many developed countries, insurance coverage has expanded to include treatments for neurological and psychiatric disorders, making therapies more accessible to a broader population. The rise in specialized healthcare facilities, such as neurology clinics and rehabilitation centers, adds another layer of market potential for CNS therapeutics. As healthcare infrastructure continues to improve, so does the market for effective and innovative CNS treatments.

Growing Investment in Research and Development

Research and development (R&D) form the backbone of the CNS therapeutics industry, and growing investment in this area serves as a substantial market driver. Additionally, pharmaceutical companies are dedicating significant resources to R&D activities, often in collaboration with academic institutions and research organizations. Such partnerships facilitate the sharing of expertise and financial resources, thereby expediting the development process. In addition, government grants, venture capital funding, and public-private partnerships are also playing an increasing role in supporting R&D efforts. This collaborative environment has led to groundbreaking discoveries, including targeted therapies and personalized medicine approaches for treating CNS disorders. The promise of high returns on investment, coupled with the ever-present demand for effective treatments, ensures that R&D funding remains a strong driver for the growth of the CNS Therapeutics industry.

Central Nervous System (CNS) Therapeutics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the central nervous system (CNS) therapeutics market report, along with forecasts at the global, regional and country levels for 2024-2032. Our report has categorized the market based on disease and application.

Breakup by Disease:

Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Multiple Sclerosis

Huntington's Disease

Amyotrophic Lateral Sclerosis

Others

Neurovascular Diseases

CNS Trauma

Mental Health
Anxiety Disorders
Epilepsy
Mood Disorders
Psychotic Disorders
Others
Infectious Diseases
CNS Cancer
Others

Neurodegenerative Diseases represent the largest market share

The report has provided a detailed breakup and analysis of the market based on the disease. This includes neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, amyotrophic lateral sclerosis, and others), neurovascular diseases, CNS trauma, mental health (anxiety disorders, epilepsy, mood disorders, psychotic disorders, and others), infectious diseases, CNS cancer, and others. According to the report, neurodegenerative diseases accounted for the largest market share.

The rising incidence of neurodegenerative diseases, such as Alzheimer's, Parkinson's, and Multiple Sclerosis is a significant market driver in the central nervous system (CNS) Therapeutics industry. As the global population ages, the prevalence of these conditions is expected to escalate, increasing the demand for effective treatments. Along with this, the socioeconomic burden these diseases place on healthcare systems and families is pushing both public and private sectors to invest heavily in research and development. Technological advancements, such as biomarker identification and gene editing, are accelerating the pace of drug discovery for neurodegenerative conditions, attracting further investment. Additionally, government initiatives and regulatory support, mainly fast-track approvals and grants, provide an impetus for pharmaceutical companies to develop innovative solutions. In addition, the growing public awareness and educational campaigns around neurodegenerative diseases are also contributing to market growth by encouraging early diagnosis and treatment. All these factors collectively create a conducive environment for the expansion of the CNS Therapeutics market in the domain of neurodegenerative diseases.

Breakup by Application:

Hospital

Clinic
Homecare
Others

A detailed breakup and analysis of the market based on the application has also been provided in the report. This includes hospital, clinic, homecare, and others.

The role of hospitals as a primary point of care for acute and chronic neurological conditions is a significant market driver in the central nervous system (CNS) therapeutics industry. Hospitals are often equipped with advanced diagnostic tools and treatment facilities, making them essential for managing complex CNS disorders. As cases of traumatic brain injuries, strokes, and emergency psychiatric episodes continue to rise, the need for specialized CNS therapeutics within hospital settings becomes increasingly crucial. The demand is further fueled by the growing number of specialized neurology departments and centers of excellence in hospitals, which require a consistent supply of CNS medications and treatments. Additionally, hospitals are key sites for clinical trials, accelerating the adoption of innovative CNS therapies.

On the contrary, the rising trend towards homecare for managing chronic and post-acute conditions is significantly influencing the Central Nervous System (CNS) therapeutics industry. As technological advancements make remote monitoring and telehealth more viable, many patients prefer receiving care in the comfort of their homes. Homecare is especially relevant for the elderly population and patients with neurodegenerative disorders who may find frequent hospital visits cumbersome. In addition, the availability of easy-to-administer medications and therapies suitable for home use is driving demand in this segment. Moreover, healthcare models are shifting towards more patient-centric approaches, further encouraging the adoption of homecare solutions. These trends not only broaden the consumer base but also open new channels for the distribution of CNS therapeutics, boosting overall market growth.

Breakup by Region:

North America
United States
Canada
Asia Pacific
China
Japan
India

South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

North America exhibits a clear dominance, accounting for the largest central nervous system (CNS) therapeutics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America exhibited the largest market segment.

The central nervous system (CNS) therapeutics industry in North America is driven by the high prevalence of CNS-related disorders, including mental health conditions, neurodegenerative diseases, and acute neurological issues. According to the Centers for Disease Control and Prevention (CDC), one in five American adults experiences mental illness each year. Furthermore, an aging population in the region significantly contributes to the increased incidence of age-related neurodegenerative diseases such as Alzheimer's and Parkinson's.

In addition, technological innovation is another significant driver, with North America often leading in the development of advanced treatments, including gene therapies and neural implants. The region also benefits from strong regulatory support, with agencies

providing fast-track approvals for innovative CNS drugs. Moreover, robust healthcare infrastructure, including advanced hospitals and a growing focus on telehealth services, facilitates easier access to treatments. Furthermore, substantial investment in research and development, both from public and private sectors, furthers innovation and the speed-to-market for new CNS therapies, collectively making North America a dynamic market for CNS therapeutics.

Competitive Landscape:

The key players are allocating significant resources to advance their understanding of CNS disorders, uncover novel treatment approaches, and develop new therapeutic agents. This involves conducting clinical trials, and preclinical studies, and leveraging cutting-edge technologies to identify potential drug candidates. Along with this, brands are leveraging advanced techniques, such as high-throughput screening, molecular modeling, and genetics to discover compounds with the potential to modulate CNS-related targets. These efforts aim to identify effective drug candidates that can address specific neurological conditions. In addition, the growing focus on personalized medicine within the CNS therapeutics field is positively influencing the market. Apart from this, companies are particularly focused on neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS. Research efforts are aimed at unraveling the underlying mechanisms of these diseases and developing disease-modifying treatments, which act as another growth-inducing factor. Furthermore, the escalating number of collaborations with research institutions, academia, and other industry players to develop new therapeutic approaches is contributing to the market.

The market research report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

AstraZeneca plc
Biogen Inc.
Eli Lilly and Company
F. Hoffmann-La Roche AG (Roche Holding)
H. Lundbeck A/S
Merck & Co. Inc.
Neurocrine Biosciences Inc.
Novartis AG
Pfizer Inc.
Sanofi S.A.
Takeda Pharmaceutical Company Limited

Teva Pharmaceutical Industries Ltd.

Recent Developments:

In May 2023, AstraZeneca plc gained authorization from the Japanese Ministry of Health, Labour, and Welfare (MHLW) to use Ultomiris (ravulizumab) to stop relapses in patients with neuromyelitis optica spectrum disease (NMOSD), including neuromyelitis optica.

In January 2023, Biogen Inc. and Alcyone Therapeutics (Alcyone) engaged in a licence and cooperation agreement to create the ThecaFlex DRx™ System from Alcyone, an implanted medical device designed for subcutaneous antisense oligonucleotide (ASO) therapy administration into the intrathecal space.

In January 2023, Capsida Biotherapeutics Inc. established a multi-year strategic partnership to develop game-changing genetic treatments for critical illnesses with Prevail Therapeutics ('Prevail'), a fully owned subsidiary of Eli Lilly and Company ('Lilly').

Key Questions Answered in This Report

1. What was the size of the global Central Nervous System (CNS) therapeutics market in 2023?
2. What is the expected growth rate of the global Central Nervous System (CNS) therapeutics market during 2024-2032?
3. What are the key factors driving the global Central Nervous System (CNS) therapeutics market?
4. What has been the impact of COVID-19 on the global Central Nervous System (CNS) therapeutics market?
5. What is the breakup of the global Central Nervous System (CNS) therapeutics market based on the disease?
6. What are the key regions in the global Central Nervous System (CNS) therapeutics market?
7. Who are the key players/companies in the global Central Nervous System (CNS) therapeutics market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 INTRODUCTION

- 4.1 Overview
- 4.2 Key Industry Trends

5 GLOBAL CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET

- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast

6 MARKET BREAKUP BY DISEASE

- 6.1 Neurodegenerative Diseases
 - 6.1.1 Market Trends
 - 6.1.2 Key Segments
 - 6.1.2.1 Alzheimer's Disease
 - 6.1.2.2 Parkinson's Disease
 - 6.1.2.3 Multiple Sclerosis
 - 6.1.2.4 Huntington's Disease

- 6.1.2.5 Amyotrophic Lateral Sclerosis
- 6.1.2.6 Others
- 6.1.3 Market Forecast
- 6.2 Neurovascular Diseases
 - 6.2.1 Market Trends
 - 6.2.2 Market Forecast
- 6.3 CNS Trauma
 - 6.3.1 Market Trends
 - 6.3.2 Market Forecast
- 6.4 Mental Health
 - 6.4.1 Market Trends
 - 6.4.2 Key Segments
 - 6.4.2.1 Anxiety Disorders
 - 6.4.2.2 Epilepsy
 - 6.4.2.3 Mood Disorders
 - 6.4.2.4 Psychotic Disorders
 - 6.4.2.5 Others
 - 6.4.3 Market Forecast
- 6.5 Infectious Diseases
 - 6.5.1 Market Trends
 - 6.5.2 Market Forecast
- 6.6 CNS Cancer
 - 6.6.1 Market Trends
 - 6.6.2 Market Forecast
- 6.7 Others
 - 6.7.1 Market Trends
 - 6.7.2 Market Forecast

7 MARKET BREAKUP BY APPLICATION

- 7.1 Hospital
 - 7.1.1 Market Trends
 - 7.1.2 Market Forecast
- 7.2 Clinic
 - 7.2.1 Market Trends
 - 7.2.2 Market Forecast
- 7.3 Homecare
 - 7.3.1 Market Trends
 - 7.3.2 Market Forecast

7.4 Others

7.4.1 Market Trends

7.4.2 Market Forecast

8 MARKET BREAKUP BY REGION

8.1 North America

8.1.1 United States

8.1.1.1 Market Trends

8.1.1.2 Market Forecast

8.1.2 Canada

8.1.2.1 Market Trends

8.1.2.2 Market Forecast

8.2 Asia-Pacific

8.2.1 China

8.2.1.1 Market Trends

8.2.1.2 Market Forecast

8.2.2 Japan

8.2.2.1 Market Trends

8.2.2.2 Market Forecast

8.2.3 India

8.2.3.1 Market Trends

8.2.3.2 Market Forecast

8.2.4 South Korea

8.2.4.1 Market Trends

8.2.4.2 Market Forecast

8.2.5 Australia

8.2.5.1 Market Trends

8.2.5.2 Market Forecast

8.2.6 Indonesia

8.2.6.1 Market Trends

8.2.6.2 Market Forecast

8.2.7 Others

8.2.7.1 Market Trends

8.2.7.2 Market Forecast

8.3 Europe

8.3.1 Germany

8.3.1.1 Market Trends

8.3.1.2 Market Forecast

- 8.3.2 France
 - 8.3.2.1 Market Trends
 - 8.3.2.2 Market Forecast
- 8.3.3 United Kingdom
 - 8.3.3.1 Market Trends
 - 8.3.3.2 Market Forecast
- 8.3.4 Italy
 - 8.3.4.1 Market Trends
 - 8.3.4.2 Market Forecast
- 8.3.5 Spain
 - 8.3.5.1 Market Trends
 - 8.3.5.2 Market Forecast
- 8.3.6 Russia
 - 8.3.6.1 Market Trends
 - 8.3.6.2 Market Forecast
- 8.3.7 Others
 - 8.3.7.1 Market Trends
 - 8.3.7.2 Market Forecast
- 8.4 Latin America
 - 8.4.1 Brazil
 - 8.4.1.1 Market Trends
 - 8.4.1.2 Market Forecast
 - 8.4.2 Mexico
 - 8.4.2.1 Market Trends
 - 8.4.2.2 Market Forecast
 - 8.4.3 Others
 - 8.4.3.1 Market Trends
 - 8.4.3.2 Market Forecast
- 8.5 Middle East and Africa
 - 8.5.1 Market Trends
 - 8.5.2 Market Breakup by Country
 - 8.5.3 Market Forecast

9 SWOT ANALYSIS

- 9.1 Overview
- 9.2 Strengths
- 9.3 Weaknesses
- 9.4 Opportunities

9.5 Threats

10 VALUE CHAIN ANALYSIS

11 PORTERS FIVE FORCES ANALYSIS

11.1 Overview

11.2 Bargaining Power of Buyers

11.3 Bargaining Power of Suppliers

11.4 Degree of Competition

11.5 Threat of New Entrants

11.6 Threat of Substitutes

12 PRICE ANALYSIS

13 COMPETITIVE LANDSCAPE

13.1 Market Structure

13.2 Key Players

13.3 Profiles of Key Players

13.3.1 AstraZeneca plc

13.3.1.1 Company Overview

13.3.1.2 Product Portfolio

13.3.1.3 Financials

13.3.1.4 SWOT Analysis

13.3.2 Biogen Inc.

13.3.2.1 Company Overview

13.3.2.2 Product Portfolio

13.3.2.3 Financials

13.3.2.4 SWOT Analysis

13.3.3 Eli Lilly and Company

13.3.3.1 Company Overview

13.3.3.2 Product Portfolio

13.3.3.3 Financials

13.3.3.4 SWOT Analysis

13.3.4 F. Hoffmann-La Roche AG (Roche Holding)

13.3.4.1 Company Overview

13.3.4.2 Product Portfolio

13.3.4.3 SWOT Analysis

- 13.3.5 H. Lundbeck A/S
 - 13.3.5.1 Company Overview
 - 13.3.5.2 Product Portfolio
 - 13.3.5.3 Financials
 - 13.3.5.4 SWOT Analysis
- 13.3.6 Merck & Co. Inc.
 - 13.3.6.1 Company Overview
 - 13.3.6.2 Product Portfolio
 - 13.3.6.3 Financials
 - 13.3.6.4 SWOT Analysis
- 13.3.7 Neurocrine Biosciences Inc.
 - 13.3.7.1 Company Overview
 - 13.3.7.2 Product Portfolio
 - 13.3.7.3 Financials
 - 13.3.7.4 SWOT Analysis
- 13.3.8 Novartis AG
 - 13.3.8.1 Company Overview
 - 13.3.8.2 Product Portfolio
 - 13.3.8.3 Financials
 - 13.3.8.4 SWOT Analysis
- 13.3.9 Pfizer Inc.
 - 13.3.9.1 Company Overview
 - 13.3.9.2 Product Portfolio
 - 13.3.9.3 Financials
 - 13.3.9.4 SWOT Analysis
- 13.3.10 Sanofi S.A.
 - 13.3.10.1 Company Overview
 - 13.3.10.2 Product Portfolio
 - 13.3.10.3 Financials
 - 13.3.10.4 SWOT Analysis
- 13.3.11 Takeda Pharmaceutical Company Limited
 - 13.3.11.1 Company Overview
 - 13.3.11.2 Product Portfolio
 - 13.3.11.3 Financials
 - 13.3.11.4 SWOT Analysis
- 13.3.12 Teva Pharmaceutical Industries Ltd.
 - 13.3.12.1 Company Overview
 - 13.3.12.2 Product Portfolio
 - 13.3.12.3 Financials

13.3.12.4 SWOT Analysis

List Of Tables

LIST OF TABLES

Table 1: Global: Central Nervous System Therapeutics Market: Key Industry Highlights, 2023 and 2032

Table 2: Global: Central Nervous System Therapeutics Market Forecast: Breakup by Disease (in Million US\$), 2024-2032

Table 3: Global: Central Nervous System Therapeutics Market Forecast: Breakup by Application (in Million US\$), 2024-2032

Table 4: Global: Central Nervous System Therapeutics Market Forecast: Breakup by Region (in Million US\$), 2024-2032

Table 5: Global: Central Nervous System Therapeutics Market: Competitive Structure

Table 6: Global: Central Nervous System Therapeutics Market: Key Players

List Of Figures

LIST OF FIGURES

Figure 1: Global: Central Nervous System Therapeutics Market: Major Drivers and Challenges

Figure 2: Global: Central Nervous System Therapeutics Market: Sales Value (in Billion US\$), 2018-2023

Figure 3: Global: Central Nervous System Therapeutics Market Forecast: Sales Value (in Billion US\$), 2024-2032

Figure 4: Global: Central Nervous System Therapeutics Market: Breakup by Disease (in %), 2023

Figure 5: Global: Central Nervous System Therapeutics Market: Breakup by Application (in %), 2023

Figure 6: Global: Central Nervous System Therapeutics Market: Breakup by Region (in %), 2023

Figure 7: Global: Central Nervous System Therapeutics (Neurodegenerative Diseases) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 8: Global: Central Nervous System Therapeutics (Neurodegenerative Diseases) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 9: Global: Central Nervous System Therapeutics (Neurovascular Diseases) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 10: Global: Central Nervous System Therapeutics (Neurovascular Diseases) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 11: Global: Central Nervous System Therapeutics (CNS Trauma) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 12: Global: Central Nervous System Therapeutics (CNS Trauma) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 13: Global: Central Nervous System Therapeutics (Mental Health) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 14: Global: Central Nervous System Therapeutics (Mental Health) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 15: Global: Central Nervous System Therapeutics (Infectious Diseases) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 16: Global: Central Nervous System Therapeutics (Infectious Diseases) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 17: Global: Central Nervous System Therapeutics (CNS Cancer) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 18: Global: Central Nervous System Therapeutics (CNS Cancer) Market

Forecast: Sales Value (in Million US\$), 2024-2032

Figure 19: Global: Central Nervous System Therapeutics (Other Diseases) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 20: Global: Central Nervous System Therapeutics (Other Diseases) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 21: Global: Central Nervous System Therapeutics (Hospital) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 22: Global: Central Nervous System Therapeutics (Hospital) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 23: Global: Central Nervous System Therapeutics (Clinic) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 24: Global: Central Nervous System Therapeutics (Clinic) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 25: Global: Central Nervous System Therapeutics (Homecare) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 26: Global: Central Nervous System Therapeutics (Homecare) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 27: Global: Central Nervous System Therapeutics (Other Applications) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 28: Global: Central Nervous System Therapeutics (Other Applications) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 29: North America: Central Nervous System Therapeutics Market: Sales Value (in Million US\$), 2018 & 2023

Figure 30: North America: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 31: United States: Central Nervous System Therapeutics Market: Sales Value (in Million US\$), 2018 & 2023

Figure 32: United States: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 33: Canada: Central Nervous System Therapeutics Market: Sales Value (in Million US\$), 2018 & 2023

Figure 34: Canada: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 35: Asia-Pacific: Central Nervous System Therapeutics Market: Sales Value (in Million US\$), 2018 & 2023

Figure 36: Asia-Pacific: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 37: China: Central Nervous System Therapeutics Market: Sales Value (in Million US\$), 2018 & 2023

Figure 38: China: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 39: Japan: Central Nervous System Therapeutics Market: Sales Value (in Million US\$), 2018 & 2023

Figure 40: Japan: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 41: India: Central Nervous System Therapeutics Market: Sales Value (in Million US\$), 2018 & 2023

Figure 42: India: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 43: South Korea: Central Nervous System Therapeutics Market: Sales Value (in Million US\$), 2018 & 2023

Figure 44: South Korea: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 45: Australia: Central Nervous System Therapeutics Market: Sales Value (in Million US\$), 2018 & 2023

Figure 46: Australia: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 47: Indonesia: Central Nervous System Therapeutics Market: Sales Value (in Million US\$), 2018 & 2023

Figure 48: Indonesia: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 49: Others: Central Nervous System Therapeutics Market: Sales Value (in Million US\$), 2018 & 2023

Figure 50: Others: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 51: Europe: Central Nervous System Therapeutics Market: Sales Value (in Million US\$), 2018 & 2023

Figure 52: Europe: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 53: Germany: Central Nervous System Therapeutics Market: Sales Value (in Million US\$), 2018 & 2023

Figure 54: Germany: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 55: France: Central Nervous System Therapeutics Market: Sales Value (in Million US\$), 2018 & 2023

Figure 56: France: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 57: United Kingdom: Central Nervous System Therapeutics Market: Sales Value

(in Million US\$), 2018 & 2023

Figure 58: United Kingdom: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 59: Italy: Central Nervous System Therapeutics Market: Sales Value (in Million US\$), 2018 & 2023

Figure 60: Italy: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 61: Spain: Central Nervous System Therapeutics Market: Sales Value (in Million US\$), 2018 & 2023

Figure 62: Spain: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 63: Russia: Central Nervous System Therapeutics Market: Sales Value (in Million US\$), 2018 & 2023

Figure 64: Russia: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 65: Others: Central Nervous System Therapeutics Market: Sales Value (in Million US\$), 2018 & 2023

Figure 66: Others: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 67: Latin America: Central Nervous System Therapeutics Market: Sales Value (in Million US\$), 2018 & 2023

Figure 68: Latin America: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 69: Brazil: Central Nervous System Therapeutics Market: Sales Value (in Million US\$), 2018 & 2023

Figure 70: Brazil: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 71: Mexico: Central Nervous System Therapeutics Market: Sales Value (in Million US\$), 2018 & 2023

Figure 72: Mexico: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 73: Others: Central Nervous System Therapeutics Market: Sales Value (in Million US\$), 2018 & 2023

Figure 74: Others: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 75: Middle East and Africa: Central Nervous System Therapeutics Market: Sales Value (in Million US\$), 2018 & 2023

Figure 76: Middle East and Africa: Central Nervous System Therapeutics Market: Breakup by Country (in %), 2023

Figure 77: Middle East and Africa: Central Nervous System Therapeutics Market
Forecast: Sales Value (in Million US\$), 2024-2032

Figure 78: Global: Central Nervous System Therapeutics Industry: SWOT Analysis

Figure 79: Global: Central Nervous System Therapeutics Industry: Value Chain Analysis

Figure 80: Global: Central Nervous System Therapeutics Industry: Porter's Five Forces
Analysis

I would like to order

Product name: Central Nervous System (CNS) Therapeutics Market Report by Disease (Neurodegenerative Diseases, Neurovascular Diseases, CNS Trauma, Mental Health, Infectious Diseases, CNS Cancer, and Others), Application (Hospital, Clinic, Homecare, and Others), and Region 2024-2032

Product link: <https://marketpublishers.com/r/C6F06728C3EBEN.html>

Price: US\$ 3,899.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C6F06728C3EBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970